Hookipa Pharma (NASDAQ:HOOK) Sees Unusually-High Trading Volume

Hookipa Pharma Inc (NASDAQ:HOOK) shares saw an uptick in trading volume on Thursday . 45,334 shares changed hands during mid-day trading, a decline of 37% from the previous session’s volume of 71,887 shares.The stock last traded at $5.50 and had previously closed at $5.50.

Wall Street Analyst Weigh In

Several research firms have weighed in on HOOK. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Hookipa Pharma in a research report on Tuesday, May 21st. HC Wainwright boosted their price objective on Hookipa Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, June 5th.

Hookipa Pharma Stock Up 9.6 %

The firm has a market capitalization of $596.67 million, a price-to-earnings ratio of -12.00 and a beta of 0.81. The stock has a 50-day moving average price of $7.50 and a 200 day moving average price of $7.43.

Hookipa Pharma (NASDAQ:HOOK) last announced its quarterly earnings results on Thursday, May 9th. The company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $2.40. The firm had revenue of $36.60 million during the quarter, compared to the consensus estimate of $3.20 million. Hookipa Pharma had a negative return on equity of 33.33% and a negative net margin of 88.73%. During the same period in the prior year, the company posted ($2.70) earnings per share. As a group, equities analysts forecast that Hookipa Pharma Inc will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hookipa Pharma

A hedge fund recently bought a new stake in Hookipa Pharma stock. Virtu Financial LLC purchased a new stake in Hookipa Pharma Inc (NASDAQ:HOOK) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 43,021 shares of the company’s stock, valued at approximately $31,000. 63.88% of the stock is owned by institutional investors and hedge funds.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.